Fiona Simpkins

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Gynecologic Oncology, Department of Ob/Gyn, Pennsylvania Hospital, Philadelphia, PA
Director, Medical Student Education for Gynecology Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Director, Resident Education for Gynecology Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
Active Staff, Gynecologic Oncology, Department of Ob/Gyn, Chester County Hospital, West Chester, PA
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 

Description of Itmat Expertise

Identifying and developing novel molecular targeted therapies for gynecological malignacies. Understanding mechanisms of resistance to targeted therapies in ovarian cancer. Developing novel in vitro and mouse models to study targeted therapies and ultimately personalize therapy based on unique individual tumor biology.

Selected Publications

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER: Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecol Oncol 145(3):413-419, Jun 2017.

Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clin Cancer Res 23(12):3097-3108, Jun 2017.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM: VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol Med 9(3):304-318, Mar 2017.

George E, Simpkins F, Ragland R, Rafail S, R Zhang, Morgan MA, Herlyn M, Brown E: Targeting the TR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models. Poster presented at: Society of Gynecologic Oncology, National Harbor, MD, Mar 2017.

Rose PG, Ali S, Moslemi-Kebria M, Simpkins F: Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. Int J Gynecol Cancer 27(3):452-458, Mar 2017.

Chen J, Solomides C, Simpkins F, Simpkins H: The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol 79(2):369-380, Feb 2017.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760(doi: 10.1172/jci.insight.89760), Jan 2017.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N: RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 1;126(8):3145-57, Aug 2016.

Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Ko E, Schmitz K: Race-based disparities in loss of functional independence after hysterectomy for uterine cancer. Support Care Cancer 24(8):3573-80: Aug 2016.

George E, Kim H, Ragland R, Brown E, Butler L, Gilad O, Tanyi J, Zhang R, Krepler C, Lee R, Morgan M, Burger R, Ko E, Kim S, Herlyn M, Simpkins F: Capitalizing on synthetic lethality in homologous recombination deficient high grade serous ovarian cancers with a novel ATR inhibitor. Poster and published as abstract for the SGO meeting. San Diego, CA, April 2016.

back to top
Last updated: 11/16/2017
The Trustees of the University of Pennsylvania